7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antihypertensive Deprescribing in Older Adults: a Practical Guide

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose of Review

          To summarise evidence on both appropriate and inappropriate antihypertensive drug withdrawal.

          Recent Findings

          Deprescribing should be attempted in the following steps: (1) identify patients with several comorbidities and significant functional decline, i.e. people at higher risk for negative outcomes related to polypharmacy and lower blood pressure; (2) check blood pressure; (3) identify candidate drugs for deprescribing; (4) withdraw medications at 4-week intervals; (5) monitor blood pressure and check for adverse events. Although evidence is accumulating regarding short-term outcomes of antihypertensive deprescribing, long-term effects remain unclear.

          Summary

          The limited evidence for antihypertensive deprescribing means that it should not be routinely attempted, unless in response to specific adverse events or following discussions between physicians and patients about the uncertain benefits and harms of the treatment.

          Perspectives

          Clinical controlled trials are needed to examine the long-term effects of deprescribing in older subjects, especially in those with comorbidities, and significant functional decline.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: found

          2018 ESC/ESH Guidelines for the management of arterial hypertension

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.

            Long-term disorders are the main challenge facing health-care systems worldwide, but health systems are largely configured for individual diseases rather than multimorbidity. We examined the distribution of multimorbidity, and of comorbidity of physical and mental health disorders, in relation to age and socioeconomic deprivation. In a cross-sectional study we extracted data on 40 morbidities from a database of 1,751,841 people registered with 314 medical practices in Scotland as of March, 2007. We analysed the data according to the number of morbidities, disorder type (physical or mental), sex, age, and socioeconomic status. We defined multimorbidity as the presence of two or more disorders. 42·2% (95% CI 42·1-42·3) of all patients had one or more morbidities, and 23·2% (23·08-23·21) were multimorbid. Although the prevalence of multimorbidity increased substantially with age and was present in most people aged 65 years and older, the absolute number of people with multimorbidity was higher in those younger than 65 years (210,500 vs 194,996). Onset of multimorbidity occurred 10-15 years earlier in people living in the most deprived areas compared with the most affluent, with socioeconomic deprivation particularly associated with multimorbidity that included mental health disorders (prevalence of both physical and mental health disorder 11·0%, 95% CI 10·9-11·2% in most deprived area vs 5·9%, 5·8%-6·0% in least deprived). The presence of a mental health disorder increased as the number of physical morbidities increased (adjusted odds ratio 6·74, 95% CI 6·59-6·90 for five or more disorders vs 1·95, 1·93-1·98 for one disorder), and was much greater in more deprived than in less deprived people (2·28, 2·21-2·32 vs 1·08, 1·05-1·11). Our findings challenge the single-disease framework by which most health care, medical research, and medical education is configured. A complementary strategy is needed, supporting generalist clinicians to provide personalised, comprehensive continuity of care, especially in socioeconomically deprived areas. Scottish Government Chief Scientist Office. Copyright © 2012 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

              The benefits of blood pressure lowering treatment for prevention of cardiovascular disease are well established. However, the extent to which these effects differ by baseline blood pressure, presence of comorbidities, or drug class is less clear. We therefore performed a systematic review and meta-analysis to clarify these differences.
                Bookmark

                Author and article information

                Contributors
                james.sheppard@phc.ox.ac.uk
                Journal
                Curr Hypertens Rep
                Curr Hypertens Rep
                Current Hypertension Reports
                Springer US (New York )
                1522-6417
                1534-3111
                26 July 2022
                26 July 2022
                2022
                : 24
                : 11
                : 571-580
                Affiliations
                [1 ]GRID grid.4991.5, ISNI 0000 0004 1936 8948, Nuffield Department of Primary Care Health Sciences, , University of Oxford, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, ; Oxford, OX2 6GG UK
                [2 ]GRID grid.29172.3f, ISNI 0000 0001 2194 6418, Maladies du Vieillissement, Gérontologie Et Soins Palliatifs”, and Inserm DCAC u1116, , CHRU-Nancy, Université de Lorraine, ; 54000 PôleNancy, France
                Author information
                http://orcid.org/0000-0002-4461-8756
                Article
                1215
                10.1007/s11906-022-01215-3
                9568439
                35881225
                b886b494-1cea-4b45-aa1e-453129c90b2b
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 24 June 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100010269, Wellcome Trust;
                Award ID: 211182/Z/18/Z
                Award Recipient :
                Categories
                Antihypertensive Agents: Mechanism of Drug Action (Me Ernst, Section Editor)
                Custom metadata
                © Springer Science+Business Media, LLC, part of Springer Nature 2022

                Cardiovascular Medicine
                blood pressure,drug-related side effects and adverse reactions,polypharmacy,ageing,medication review,evidence-based medicine

                Comments

                Comment on this article